The central importance of aberrant K-RAS activation has been well established in human pancreatic cancer, where a vast majority of patients experience limited clinical options, rapid tumor relapse and metastasis, and largely dismal outcomes. This evidence concerns the gene KRAS and familial pancreatic carcinoma.